(CercleFinance.com) – The title AstraZeneca shows a heavy decline on Monday on the London Stock Exchange following the presentation by the pharmaceutical group of results considered mixed in lung cancer.
The stock is currently down 6.7%, the biggest drop in Britain’s FTSE 100 index by far.
The laboratory reported this morning that the phase III trial evaluating datopotamab deruxtecan (Dato-Dxd) had demonstrated “a statistically significant improvement” in progression-free survival compared to docetaxel, the current reference chemotherapy.
The study involves patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) treated with at least one prior therapy.
Regarding overall survival, AstraZeneca believes that the data is not yet sufficiently advanced, which means that the trial will continue as planned in order to evaluate it with greater maturity.
In a reaction note, UBS analysts believe that these data are rather ‘difficult to interpret’.
The design office, which recalls that market expectations around Dato-dxd are high, also says it is worried about side effects presented as relatively ‘serious’.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
